Literature DB >> 3678739

Hepatitis B virus deoxyribonucleic acid in serum during hepatitis B e antigen clearance in corticosteroid-treated severe chronic active hepatitis B.

J R Wood1, A J Czaja, H F Taswell, J Ludwig, J Rakela, R Chase.   

Abstract

The relationship between hepatitis B virus deoxyribonucleic acid in serum and histologic activity was determined in 11 patients with corticosteroid-treated severe chronic active hepatitis B who underwent clearance of hepatitis B e antigen. All patients cleared hepatitis B virus deoxyribonucleic acid from the serum, and clearance preceded the loss of hepatitis B e antigen by 9-49 mo (mean 24 +/- 4 mo). Seropositivity for hepatitis B virus deoxyribonucleic acid was always associated with histologic features of chronic active hepatitis. Resolution of histologic activity followed the loss of hepatitis B virus deoxyribonucleic acid from the serum and it preceded clearance of hepatitis B e antigen in all patients. A transient elevation of serum aspartate aminotransferase activity occurred in 5 patients at the time that absence of hepatitis B virus deoxyribonucleic acid in serum was first demonstrated, and it was followed by resolution of histologic activity. The serum level of hepatitis B virus deoxyribonucleic acid slowly decreased or remained unchanged in all but 1 patient during long-term corticosteroid therapy. We conclude that hepatitis B virus deoxyribonucleic acid in serum is associated with histologic activity in corticosteroid-treated patients with severe chronic active hepatitis B. Disappearance of hepatitis B virus deoxyribonucleic acid from the serum precedes the loss of histologic activity and clearance of hepatitis B e antigen. Serum hepatitis B virus deoxyribonucleic acid levels usually do not increase during long-term corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3678739     DOI: 10.1016/0016-5085(87)90248-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  3 in total

1.  Nucleotide sequence analysis of precore and proximal core regions in patients with chronic hepatitis B treated with interferon.

Authors:  T Laskus; J Rakela; D H Persing
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

2.  Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.

Authors:  L Guillevin; F Lhote; F Sauvaget; P Deblois; F Rossi; D Levallois; J Pourrat; B Christoforov; C Trépo
Journal:  Ann Rheum Dis       Date:  1994-05       Impact factor: 19.103

3.  Treatment of hepatitis B virus-related polyarteritis nodosa: two case reports and a review of the literature.

Authors:  D H Deeren; A I De Backer; M L N G Malbrain; H Verbraeken; D Blockmans
Journal:  Clin Rheumatol       Date:  2004-02-11       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.